Home
What CME Do I Need?
Single Topics
Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy

Earn up to 13.00 CME credits

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy

Learn to formulate an integrated psychopharmacologic and psychotherapeutic treatment approach for patients with major depression, bipolar illness, and anxiety disorders.

See Reviews Media Formats

$895.00

Current Stock:

Quantity:

Quick Facts

Overview

Learn Now: Advances in Psychopharmacology and Psychotherapy

In addition to highlighting emerging strategies in the assessment and treatment of major depression and bipolar illness, this online CME course defines approaches to mood and anxiety disorders, including psychodynamic psychotherapy, cognitive and behavioral therapy, interpersonal psychotherapy for depression and other psychotherapeutic approaches.

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy also addresses comorbid conditions such as Axis II personality disorders, management of patients with medical conditions, management of the geriatric patient, and more. It’s psychiatry CME that offers insight into:

Issues around the choice of specific antidepressants, mood stabilizers and anti-anxiety medications
Psychopharmacologic management of the treatment resistant patient
Recent developments in neuropsychiatry, including brain imaging and therapeutic stimulation techniques
Therapeutic efficacy and risks associated with ketamine administration
Obsessive-compulsive disorders including skin-picking, trichotillomania and body dysmorphic
Management of anxiety in patients vulnerable to abuse of alcohol
And more…

Topics / Speakers

All lectures by Russell G. Vasile, MD

Assessment and Treatment of Major Depressive Disorder

Psychopharmacologic Management of Bipolar Disorder Emerging Perspectives

Anxiety Disorders- Assessment and Pharmacotherapy

Suicide Assessment and Prevention, Psychotherapy of Depression and Perspectives on Personality Disorder

Assessment and Management of Depression in the Elderly and Brain Imaging

Faculty

Course Director

Lawrence E. Lifson, MD

Dr. Lifson is a Lecturer on Psychiatry at Harvard Medical School. He is the Director of the Continuing Education Program at Beth Israel Deaconess Medical Center, and a faculty member at Boston Psychoanalytic Society and Institute. He is a co-chair for the Continuing Education Program at Boston Psychoanalytic Society and Institute. Dr. Lifson is a Distinguished Life Fellow of the American Psychiatric Association, and the 2012 recipient of the Massachusetts Psychiatric Society’s “Outstanding Psychiatrist in Education Award.” He is the 2016 Recipient of Tufts Medical Alumni Association Dean’s Award, and has received the 2019 American Psychoanalytic Association Edith Sabshin Teaching Award. He is editor of Understanding Therapeutic Action: Current Concepts of Cure and The Mental Health Practitioner and the Law and The Psychology of Investing.

Faculty

Russell G. Vasile, MD

Dr. Vasile is Associate Professor of Psychiatry at Harvard Medical School and Director of the Affective Disorders Consultation Program at the Beth Israel Deaconess Medical Center. He has published in diverse areas related to the assessment and treatment of anxiety and affective disorders. Dr. Vasile is also a graduate of the Boston Psychoanalytic Society and Institute, and a past recipient of the Elvin V. Semrad Award for Excellence in Teaching at the Massachusetts Mental Health Center.

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Harvard Medical School designates this enduring material for a maximum of 13.00 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Original Release: October 15, 2021

Termination Date: January 31, 2024
(Please note that AMA PRA Category 1 Credits™ will no longer be issued for the activity after this date)

Estimated Time to Complete the Activity: 13.00 hours

CME credit is awarded upon successful completion of a course evaluation and post-test.

ACGME Competencies

This course is designed to meet one or more of the following Accreditation Council for Graduate Medical Education Competencies:

Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills

Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Disclosure information for all individuals in control of the content of the activity is located on the disclosure statement in the PDF and printed syllabus.

Learning Objectives

Upon completion of this activity, participants will be better able to:

Evaluate emerging strategies in the use of psychotropic medications in the treatment of major depression and anxiety disorders and integrate psychopharmacologic treatments into psychotherapy strategies in treating depressed and anxious patents
Describe strategies for the psychopharmacological and psychotherapeutic management of treatment resistant depression
Summarize the emerging role of ketamine in the treatment of major depression and suicidal behavior
Explore the role of novel enhancements to treatment of mood disorders including omega 3 fatty acids, 1 methylfolate and zinc
Discuss the role of electroconvulsive therapy and Transcranial Magnetic Stimulation in treatment resistant depressive disorders
Examine new developments in the treatment of depression in bipolar patients with a focus on newer medications including lurasidone and cariprazine
Identify an evidence-based approach to suicide risk assessment and prevention of suicide
Appreciate the role of lithium carbonate in combination with other mood stabilizing agents
Give examples of recent developments in psychotherapeutic approaches to treating Bipolar patients, including cognitive, behavioral and expressive psychotherapy techniques
Integrate psychodynamic assessment, psychotherapy and psychopharmacology into management of depression and anxiety disorders
Assess the role of Cognitive Behavioral Therapy (CBT) in the treatment of depression and anxiety disorders
Compare recent developments in the implementation of CBT, including Commitment and Acceptance Therapy and inclusion of exposure therapy in CBT
Report on the latest applications for computer- based treatment of OCD and other anxiety disorders
Describe new psychopharmacological and psychotherapeutic techniques in the treatment of PTSD including exposure and response prevention and virtual reality techniques utilized to treat PTSD secondary to exposure to combat
Formulate an integrated psychopharmacological and psychotherapeutic approach to personality-disordered patients in the borderline and severely narcissistic spectrum presenting with depression and anxiety
Manage anxiety disorders in patients vulnerable to alcohol abuse and psychological dependence on marijuana, including the use of non-benzodiazepine anti-anxiety agents such as pregabalin and buspirone
Formulate strategies for treating patients with marijuana abuse disorder, including discussion of newly emerging psychopharmacological and psychotherapeutic techniques

Target Audience

This educational activity was designed for health professionals in the fields of psychiatry, psychology, nursing, social work, counseling, medicine, pediatrics, and surgery.

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy